Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Clinical diagnosis of perimenopause and menopause
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Do not let menopause mask acute disease
Collapse, chest pain, focal neurology, severe headache, suicidal crisis, pregnancy-related pain or bleeding, and heavy or postmenopausal bleeding are not explained safely by a routine menopause label.
Action: Assess observations and pregnancy possibility, quantify bleeding, examine for the suspected acute cause, and use emergency, pregnancy, mental-health or suspected-cancer pathways without waiting for hormone results.
Purpose and principles
Diagnose the menopausal transition from age, symptoms and menstrual context while using laboratory tests selectively and recognising pregnancy, premature ovarian insufficiency and important alternative disease.
Perimenopause is a clinical transition, not a single hormone concentration. Ovarian follicle activity becomes erratic, cycles alter and symptoms fluctuate before the final menstrual period. Ask when the cycle changed, whether intervals shortened or lengthened, whether flow changed and when vasomotor, sleep, mood, musculoskeletal, sexual or genitourinary symptoms began. Establish pregnancy possibility, contraception, medicines, medical or surgical ovarian treatment, hysterectomy and family timing of menopause. Use language that reflects the person's anatomy and identity without assuming that every mid-life symptom is hormonal.
For an otherwise healthy person aged 45 or over, NICE advises clinical identification. Perimenopause is supported by recently starting hot flushes or sweats together with menstrual-cycle change. Menopause is identified after 12 months of amenorrhoea if hormonal contraception is not obscuring bleeding. A hysterectomy removes that marker, so a coherent cluster of vasomotor and other symptoms is used. The final menstrual period can only be dated retrospectively, and fertility declines before it disappears; contraception advice therefore remains separate from diagnosis.
Indications, selection and cautions
Typical perimenopause
New hot flushes or night sweats with a recent change in cycle length or flow after age 45 usually supports a clinical diagnosis without hormone measurement.
Natural menopause
At least twelve consecutive months without menstruation in someone not using hormonal contraception identifies menopause retrospectively after pregnancy and other causes are considered.
Menopause after hysterectomy
Without menstrual bleeding as a marker, a characteristic combination and evolution of vasomotor, sleep, mood and genitourinary symptoms supports the diagnosis.
Early menopause or POI
Compatible symptoms and menstrual disturbance from age 40 to 44 suggest early menopause, while onset below 40 requires a premature-ovarian-insufficiency pathway.
Atypical symptom pattern
Persistent constitutional symptoms, focal signs, marked endocrine features or bleeding outside the expected pattern redirects assessment toward a specific alternative diagnosis.
Red flags requiring action
Vaginal bleeding more than 12 months after the final natural menstrual period requires assessment as postmenopausal bleeding rather than reassurance about cycle variability.
Amenorrhoea with pelvic pain, bleeding, syncope or shoulder-tip pain requires an immediate pregnancy test and urgent exclusion of ectopic pregnancy.
Method and interpretation
01Clinical history and menstrual chronologyFirst step
Why
Identify a typical transition and determine whether bleeding, treatment or surgery obscures the final menstrual period.
Interpretation and limitations
New vasomotor symptoms plus cycle change after 45 supports perimenopause; twelve months of untreated amenorrhoea supports menopause, but neither excludes red-flag pathology.
02Urine or serum hCG
Why
Exclude pregnancy when amenorrhoea, altered bleeding or treatment choice makes conception clinically relevant.
Interpretation and limitations
A positive result changes medicine safety and requires pregnancy localisation if pain or bleeding is present; a negative result does not itself confirm menopause.
03Serum FSH in a defined age group
Why
Support diagnosis at age 40 to 45 or investigate suspected ovarian insufficiency below 40.
Interpretation and limitations
Interpret against symptoms, cycle timing and hormone use; one fluctuating value does not diagnose POI, and combined contraception or high-dose progestogen invalidates the test.
04Targeted endocrine or haematology tests
Why
Investigate a plausible alternative such as thyroid disease, hyperprolactinaemia, anaemia or androgen excess.
Interpretation and limitations
Choose TSH, prolactin, full blood count, ferritin or androgens from specific clinical findings rather than using them as a routine menopause screen.
Clinical next steps
01IdentifyUse age and pattern firstFirst stepMenopause-associated symptoms or menstrual change prompts assessment.+
1Document menstrual chronology, vasomotor and genitourinary symptoms, functional effect, pregnancy possibility, contraception and treatment history.
2At age 45 or over with a typical pattern, make a clinical diagnosis without a routine reproductive-hormone panel.
3If hysterectomy or hormonal treatment obscures bleeding, interpret the symptom cluster and avoid inventing a final-menstrual-period date.
02DiscriminateTest a competing explanationAge, examination or symptom pattern is atypical, or the diagnosis changes important care.+
1Use hCG whenever pregnancy remains possible and urgently localise pregnancy if pain, bleeding or instability accompanies a positive result.
2Reserve FSH for ages 40 to 45 or suspected POI below 40, avoiding suppressed states in which it cannot answer the question.
Risks, monitoring and follow-up
Review symptoms, quality of life, adverse effects and any bleeding three months after treatment begins or changes, then at least annually once stable.
Revisit contraception at each relevant review because a menopause diagnosis is retrospective and HRT does not prevent pregnancy.
Record the timing, volume and context of any new bleeding and escalate postmenopausal, persistent, postcoital or heavy bleeding through the appropriate pathway.
Reassess mood, sleep and function rather than assuming all deterioration is hormonal, including direct enquiry about self-harm when clinically indicated.
Refer for specialist menopause or reproductive assessment when onset is before 45, diagnosis remains uncertain, comorbidity complicates treatment or symptoms persist despite reasonable adjustments.
Special situations
The diagnosis is longitudinal
Cycle and symptom evolution over months is usually more informative than one reproductive-hormone value obtained during fluctuating ovarian activity.
Amenorrhoea has context
Twelve months without bleeding identifies natural menopause only when pregnancy, hormonal contraception, uterine surgery and other causes do not explain the absence.
FSH has a narrow job
Its useful diagnostic role is concentrated in suspected early menopause or POI, not routine confirmation of a typical transition after age 45.
Symptoms remain plural
Vasomotor, sleep, mood, musculoskeletal, sexual and genitourinary effects vary independently, so severity and treatment goals should be recorded rather than assumed.
Bleeding stays separate
Perimenopause can make cycles irregular, but that observation never cancels pregnancy assessment, cervical evaluation or postmenopausal-bleeding referral when indicated.
Common pitfalls
01
Ordering FSH, oestradiol and AMH routinely in a healthy symptomatic person aged over 45 and treating fluctuating results as a diagnostic contest.
02
Calling twelve months of amenorrhoea menopause without checking whether hormonal contraception, hysterectomy, pregnancy or another endocrine condition explains it.
03
Using a normal FSH during combined hormonal contraception to exclude ovarian insufficiency despite pharmacological suppression.
04
Attributing palpitations, weight loss, severe headache, focal neurology or marked mood disturbance to menopause without assessing the specific alternative.
05
Reassuring about postmenopausal or persistent intermenstrual bleeding because irregular bleeding occurred earlier in the transition.
06
Discussing symptom treatment without fertility, contraception, bone, cardiovascular or psychological implications of an early diagnosis.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Clinical diagnosis after forty-five
A healthy 49-year-old has newly developed hot flushes and increasingly irregular periods over eight months. She uses condoms, takes no hormones and has no red-flag symptoms. What is the most appropriate diagnostic approach?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Laboratory tests often create false certainty because FSH and oestradiol fluctuate markedly during the transition. In those aged 45 or over, do not use AMH, inhibin A, inhibin B, oestradiol, ovarian volume or antral-follicle count to identify menopause. An isolated FSH is also unnecessary in this group and is uninterpretable during combined hormonal contraception or high-dose progestogen treatment. Serum FSH has a narrower role at ages 40 to 45 when symptoms and cycle change suggest early menopause, and below 40 when premature ovarian insufficiency is possible.
Selective testing should answer a competing hypothesis. Check hCG for amenorrhoea or irregular bleeding when pregnancy is possible. TSH is useful when weight change, tremor, palpitations, heat intolerance or altered cycles could reflect thyroid disease. Prolactin is appropriate for galactorrhoea, headaches or persistent amenorrhoea; a full blood count and iron studies help when bleeding is heavy or fatigue disproportionate. Consider androgen testing for rapid hirsutism or virilisation and pelvic examination or imaging for pain, pressure, a mass or abnormal bleeding. None of these is a routine confirmation panel for an otherwise typical transition.
Bleeding deserves independent classification. Erratic bleeding can occur in perimenopause, but pregnancy, medication effects, cervical disease, polyps, fibroids, endometrial pathology and bleeding disorders remain possible. Ask about heaviness, flooding, clots, intermenstrual or postcoital bleeding and risk factors for endometrial cancer. Any new bleeding after 12 months of natural amenorrhoea is postmenopausal bleeding until assessed. Bleeding on systemic HRT follows a separate timing- and risk-based pathway rather than resetting the date of natural menopause.
A diagnostic consultation should validate symptoms while preserving uncertainty where it matters. Explain the expected biology, discuss fertility and contraception, offer symptom management and address cardiovascular, bone and psychological health. Review at three months after starting treatment to assess efficacy, tolerability and bleeding, then annually if stable. Refer for menopause or reproductive expertise when symptoms begin unusually early, diagnosis remains uncertain, complex comorbidity constrains treatment, or initial management is ineffective.
Key points
In an otherwise healthy person aged 45 or over, diagnose perimenopause clinically when newly developing vasomotor symptoms accompany menstrual-cycle change; routine hormone tests are unnecessary.
Diagnose menopause clinically after at least 12 months without a period when the person is not using hormonal contraception; after hysterectomy, use the characteristic symptom pattern because bleeding cannot mark the transition.
Do not use anti-Müllerian hormone, inhibins, oestradiol, antral-follicle count or ovarian volume to identify perimenopause or menopause in people aged 45 or over.
Consider serum FSH only for people aged 40 to 45 with compatible symptoms and cycle change, or those under 40 in whom menopause or premature ovarian insufficiency is suspected.
Do not use FSH to diagnose menopause during combined oestrogen-progestogen contraception or high-dose progestogen treatment because suppression makes the result misleading.
Exclude pregnancy whenever biologically possible; HRT neither prevents ovulation nor provides contraception, and irregular cycles can still contain an ovulation.
Investigate targeted alternatives when the pattern is atypical rather than ordering a broad menopause panel: examples include TSH, prolactin, full blood count or pelvic assessment according to the history.
New focal neurological symptoms, exertional chest pain, severe breathlessness or unilateral leg swelling needs acute assessment and must not be attributed to hot flushes or anxiety.
Marked weight loss, persistent fever, galactorrhoea, visual-field change, virilisation or a pelvic mass indicates an alternative endocrine, malignant or structural diagnosis.
Severe depressive symptoms, mania, psychosis, self-neglect or thoughts of suicide require same-day mental-health risk assessment alongside symptom care.
05Bleeding-directed pelvic assessment
Why
Identify cervical, uterine, endometrial or adnexal disease when bleeding, pain or examination findings are abnormal.
Interpretation and limitations
Postmenopausal bleeding, a suspicious cervix, a pelvic mass or persistent intermenstrual bleeding follows its relevant urgent imaging, biopsy or referral pathway.
3Select thyroid, prolactin, haematology, androgen or pelvic investigations only when the history or examination provides a corresponding hypothesis.
03CloseLink diagnosis to continuing careA clinical diagnosis is made or a specialist work-up has been arranged.+
1Explain fertility uncertainty, contraception needs, symptom options and warning signs using shared decision making.
2Create a specific plan for abnormal bleeding, early menopause, complex medical history or psychological distress rather than subsuming these under menopause.
3Review treatment at three months and then annually, with earlier reassessment for adverse effects, poor response or a changed symptom pattern.
Record the effect on sleep, mood, sexual function, work, relationships and quality of life, then review any chosen treatment at three months and annually thereafter.